Industry Leader

Although virtual marking has been available for nearly a decade, courts have provided little specific guidance. Still, there are some points to keep in mind for virtual marking.

In the life sciences sector, quantum computing holds great potential for transforming data-heavy processes, from accelerating drug discovery to simulating clinical trials, and is one of the key technological areas we predict will impact life sciences for the better.

Given everything that we have learned from the COVID-19 situation,  healthcare leaders can implement the following key takeaways to help them successfully weather the next storm that comes our way.

Precision medicine necessitates precision research, which necessitates getting highly specific biospecimens to researchers on demand, in alignment with their demand. Researchers shouldn’t have to adjust their research to whatever specimens are available; supply needs to fit the research.

For life science executives, deciding how to manage your overall portfolio, including illiquid or complex assets, is an important step in preserving both your financial and philanthropic legacies.

Looking back, it’s ironic that we named our company LaunchPad Medical. Our inspiration for the name came from our plan to take challenging ideas and materials and “launch” them into the medical space to revolutionize healthcare. But it never dawned on me to take our research to the International Space Station (ISS).

Organizations and their leaders often focus on what needs to improve, but research shows there is more to be gained from a strengths-based approach. Coaching around strengths yields greater optimism and success.

With the right preparation and investments, entering the federal government market can lead to considerable growth and visibility for your company. Consider the following tips for increased chances of success.

The medical device market is about to succumb to a raft of substantial international regulatory changes, starting with Europe’s MDR in May 2020, as public pressure and industry authorities call for greater accountability for patient safety.

Typically, there are two paths biotechs take when going public — seeking VC funding or raising capital via a reverse merger. However, INmune Bio chose a third path.